Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan [TechCrunch]
Unity Biotechnology, Inc. (NASDAQ: UBX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $6.00 price target on the stock.
UNITY Biotechnology Reports Granting of New Employment Inducement Award
UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer